Ihlaziywe nge-10 Juni 2022, ngokulandela izindululo zethutyana ezihlaziyiweyo.
IQela leeNgcebiso ngoBuchule be-WHO (i-SAGE) likhuphe iingcebiso zexeshana zokusetyenziswa kogonyo lwe-Sinopharm ngokuchasene ne-COVID-19. Eli nqaku linika isishwankathelo sezo ngcebiso zethutyana; ungafikelela kuxwebhu olupheleleyo lwesikhokelo apha.
Nantsi into ekufuneka uyazi.
Ngubani onokugonywa?
Isitofu sokugonya sikhuselekile kwaye sisebenza kubo bonke abantu abaneminyaka eyi-18 nangaphezulu. Ngokuhambelana ne-WHO Prioritization Roadmap kunye ne-WHO Values Framework, abantu abadala abadala, abasebenzi bezempilo kunye nabantu abakhubazekileyo kufuneka babekwe phambili.
Ugonyo lweSinopharm lunokunikwa abantu ababene-COVID-19 kwixesha elidlulileyo. Kodwa abantu banokukhetha ukulibazisa ugonyo kangangeenyanga ezi-3 emva kosulelo.
Ngaba abasetyhini abakhulelweyo nabancancisayo kufuneka bagonywe?
Idatha ekhoyo yesitofu sokugonya se-COVID-19 i-Sinopharm kubasetyhini abakhulelweyo abanelanga ukuvavanya ukusebenza kwesitofu sokugonya okanye imingcipheko enxulumene nesitofu ekukhulelweni. Nangona kunjalo, olu gonyo sisitofu sokugonya esingasebenziyo esine-adjuvant esisetyenziswa rhoqo kwezinye izitofu ezininzi ezineprofayile yokhuseleko ebhaliweyo, kubandakanywa nabasetyhini abakhulelweyo. Ukusebenza kogonyo lwe-COVID-19 iSinopharm kubasetyhini abakhulelweyo ke kulindeleke ukuba kuthelekiswe naleyo ibonwa kwabasetyhini abangakhulelwanga abakwiminyaka efanayo.
Okwangoku, i-WHO icebisa ukuba kusetyenziswe isitofu sokugonya i-COVID-19 iSinopharm kubasetyhini abakhulelweyo xa izibonelelo zokugonya kowasetyhini okhulelweyo zodlula ubungozi obunokubakho. Ukunceda abasetyhini abakhulelweyo benze olu vavanyo, kufuneka banikwe ulwazi malunga nobungozi be-COVID-19 ekukhulelweni; iinzuzo ezinokubakhona zogonyo kwimeko ye-epidemiological yendawo; kunye nemida yangoku yedatha yokhuseleko kubasetyhini abakhulelweyo. I-WHO ayicebisi uvavanyo lokukhulelwa ngaphambi kokugonywa. I-WHO ayikukhuthazi ukubambezeleka kokukhulelwa okanye kuthathelwe ingqalelo ukuphelisa ukukhulelwa ngenxa yokugonywa.
Ukusebenza kogonyo kulindeleke ukuba kufane kwabasetyhini abancancisayo njengabanye abantu abadala. I-WHO icebisa ukuba kusetyenziswe isitofu sokugonya i-COVID-19 iSinopharm kubasetyhini abancancisayo njengabanye abantu abadala. I-WHO ayicebisi ukuyeka ukuncancisa emva kokugonywa.
Ngoobani isitofu esingakhuthazwayo?
Abantu abanembali ye-anaphylaxis kulo naliphi na icandelo lesitofu sokugonya akufanele bathathe.
Nabani na onobushushu bomzimba obungaphezulu kwe-38.5ºC kufuneka aluhlehlise ugonyo de angabinafiva.
Ngaba ikhuselekile?
I-SAGE ivavanye ngokucokisekileyo idatha kumgangatho, ukhuseleko kunye nokusebenza kwesitofu sokugonya kwaye uye wacebisa ukusetyenziswa kwayo kubantu abaneminyaka eyi-18 nangaphezulu.
Idatha yokhuseleko ilinganiselwe kubantu abangaphezu kweminyaka engama-60 ubudala (ngenxa yenani elincinci labathathi-nxaxheba kulingo lwezonyango). Ngelixa kungekho mahluko kwiprofayili yokhuseleko yesitofu sokugonya kubantu abadala xa kuthelekiswa namaqela aselula anokulindeleka, amazwe acinga ukusebenzisa olu gonyo kubantu abangaphezulu kweminyaka engama-60 kufuneka agcine uhlolo olusebenzayo lokhuseleko.
Ingaba isitofu sokugonya sisebenza kangakanani?
Ulingo olukhulu lwamazwe amaninzi lweSigaba sesi-3 lubonise ukuba iidosi ezi-2, ezilawulwa ngesithuba seentsuku ezingama-21, zisebenza nge-79% ngokuchasene nolosulelo lwe-SARS-CoV-2 oluneempawu kwiintsuku ezili-14 okanye ngaphezulu emva kwedosi yesibini. Isitofu sokugonya ngokuchasene nokulaliswa esibhedlele sasingama-79%.
Ulingo aluzange luyilwe kwaye lunikwe amandla ukubonisa ukusebenza ngempumelelo ngokuchasene nesifo esiqatha kubantu abane-commorbidities, ekukhulelweni, okanye kubantu abaneminyaka engama-60 ubudala nangaphezulu. Abasetyhini bebengamelwanga ngokwaneleyo kweli tyala. Ubude bexesha eliphakathi lokulandelwa okukhoyo ngexesha lokuphononongwa kobungqina kwakuyientsuku ze-112.
Amanye amalingo amabini okusebenza ayaqhubeka kodwa idatha ayikafumaneki.
Yeyiphi idosi ecetyiswayo?
I-SAGE icebisa ukuba kusetyenziswe isitofu sokugonya i-Sinopharm njengemilinganiselo emi-2 (0.5 ml) enikwe nge-intramuscularly.
I-SAGE icebisa ukuba i-dose yesithathu, idosi eyongezelelweyo yesitofu sokugonya i-Sinopharm inikwe abantu abaneminyaka engama-60 nangaphezulu njengenxalenye yokwandiswa koluhlu oluphambili. Idatha yangoku ayibonisi imfuno yedosi eyongezelelweyo kubantu abangaphantsi kweminyaka engama-60 ubudala.
I-SAGE yenza isincomo sokuba abantu ababuthathaka nabangakhuselekanga ngokuphakathi kufuneka banikwe idosi eyongezelelweyo yesitofu sokugonya. Oku kungenxa yokuba eli qela alifane liphendule ngokufanelekileyo kugonyo kulandela uluhlu oluqhelekileyo logonyo olusisiseko kwaye basemngciphekweni omkhulu wesifo esimandundu se-COVID-19.
I-WHO icebisa ikhefu leeveki ezi-3-4 phakathi kwedosi yokuqala neyesibini yochungechunge oluphambili. Ukuba idosi yesibini ilawulwa ngaphantsi kweeveki ezi-3 emva kokuqala, idosi ayifuni ukuphinda iphindwe. Ukuba ukulawulwa kwedosi yesibini kulibaziseke ngaphezu kweeveki ezi-4, kufuneka kunikwe ngokukhawuleza ithuba elinokwenzeka. Xa unikezela ngedosi eyongezelelweyo ukuya ngaphezulu kwama-60s, i-SAGE icebisa ukuba amazwe ekuqaleni kufuneka ajolise ekwandiseni ukhuseleko lwedosi emi-2 kwabo bantu, kwaye emva koko anike idosi yesithathu, ukuqala ngawona maqela amadala.
Ngaba idosi yokomeleza iyacetyiswa kwesi sitofu?
Umthamo we-booster unokuqwalaselwa kwi-4 - kwiinyanga ze-6 emva kokugqitywa kwechungechunge lokugonya oluphambili, ngokuqala ngamaqela aphezulu-ukusetyenziswa kwamaqela, ngokuhambelana ne-WHO Prioritization Roadmap.
Izibonelelo zogonyo lwe-booster zibonwa emva kokunyuka kobungqina bokuncipha kokusebenza kogonyo ngokuchasene nosulelo oluthambileyo lwe-SARS-CoV-2 ngokuhamba kwexesha.
Nokuba i-homologous (imveliso yesitofu esahlukileyo kwi-Sinopharm) okanye i-heterologous (idosi ye-booster ye-Sinopharm) ingasetyenziswa. Uphononongo olwenziwe e-Bahrain lufumanise ukuba ukonyuswa kwe-heterologous kubangele impendulo ephezulu yomzimba yokuzikhusela xa kuthelekiswa nokunyuswa kwe-homologous.
Ingaba esi sitofu 'singaxutywa kwaye sithelekiswe' nezinye izitofu?
I-SAGE yamkela iidosi ezimbini ze-heterologous zezitofu zokugonya ze-WHO EUL COVID-19 njengothotho olupheleleyo olusisiseko.
Ukuqinisekisa ugonyo olulinganayo okanye oluncomekayo okanye ugonyo olusebenzayo nokuba yeyiphi yezitofu zokugonya ze-WHO EUL COVID-19 mRNA (Pfizer okanye iModerna) okanye i-WHO EUL COVID-19 izitofu zokugonya (i-AstraZeneca Vaxzevria/COVISHIELD okanye iJanssen) zinokusetyenziswa njengedosi yesibini elandelayo idosi yokuqala kunye nesitofu sokugonya seSinopharm sixhomekeke ekufumanekeni kwemveliso.
Ngaba iyaluthintela usulelo kunye nosulelo?
Okwangoku akukho datha ikhoyo ikhoyo enxulumene nefuthe leSinopharm ekusasazeni i-SARS-CoV-2, intsholongwane ebangela isifo se-COVID-19.
Okwangoku, i-WHO ikhumbuza ngemfuneko yokugcina kunye nokomeleza amanyathelo ezempilo kawonke-wonke asebenzayo: ukugquma ubuso, ukuhamba kude ngokomzimba, ukuhlamba izandla, ukuphefumla kunye nococeko lokukhohlela, ukuphepha izihlwele kunye nokuqinisekisa ukungena komoya okwaneleyo.
Ngaba iyasebenza ngokuchasene neentlobo ezintsha zentsholongwane ye-SARS-CoV-2?
I-SAGE okwangoku icebisa ukuba kusetyenziswe esi sitofu, ngokwe-WHO Prioritization Roadmap.
Njengoko idatha entsha ifumaneka, i-WHO iya kuhlaziya iingcebiso ngokufanelekileyo. Esi sitofu sokugonya ayikavavanywa kumxholo wokusasazwa kokwahluka okuxhaphakileyo okuxhalabisayo.
Ingaba esi sitofu sithelekiseka njani nezinye izitofu esele zisetyenziswa?
Asinako ukuthelekisa izitofu zokugonya intloko ukuya-entloko ngenxa yeendlela ezahlukeneyo ezithathiweyo ekuyileni izifundo ezifanelekileyo, kodwa lilonke, zonke izitofu ezithe zafikelela kuLuhlu lokuSebenzisa oluNgxamisekileyo lwe-WHO zisebenza kakhulu ekuthinteleni isifo esiqatha kunye nokulaliswa esibhedlele ngenxa ye-COVID-19. .
Ixesha lokuposa: Jun-15-2022